News 2007

Pfizer acquires Coley Pharmaceutical Group

Date: 30/11/2007

New York, USA – Pfizer announced today that it has acquired Coley Pharmaceutical Group. See the press release here.

First closing of Thuja Capital Healthcare Fund

Date: 14/09/2007

Utrecht, The Netherlands. Thuja Capital announces the first closing of Thuja Capital Healthcare Fund. More information can be found in the press release.

DeveloGen and Teva enter into exclusive license agreement

Date: 19/06/2007

Goettingen, Germany – DeveloGen and Teva entered into an exclusive license agreement for DeveloGen’s protein kinase B technology for the treatment of cancer. For more information please be referred to the press release.

OMRIX receives FDA approval for its liquid fibrin sealant, Evicel, for use in vascular surgery

Date: 15/05/2007

New York, USA – OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets protein-based biosurgery and passive immunotherapy products, announced that on May 9, 2007, the U.S. Food and Drug Administration, or FDA, approved its supplemental Biologics License Application, or sBLA, to market its liquid fibrin sealant, Evicel(TM), in vascular surgery. (more…)

DeveloGen sells its diabetes drug to Cial Biotechnologies

Date: 17/04/2007

Goettingen, Germany/Tel-Aviv, Israel — DeveloGen Israel Limited (“DeveloGen”), a wholly owned subsidiary of DeveloGen AG, and Andromeda Biotech Ltd. (“Andromeda”), a newly formed wholly owned subsidiary of Clal Biotechnology Industries Ltd. (“Clal”), today announced that DeveloGen and Andromeda have signed a term sheet for an asset purchase agreement for DeveloGen’s DiaPep277® program for the treatment of type 1 diabetes. (more…)

Harrold van Barlingen interviewed by C2W Manazine

Date: 17/03/2007

Uterecht, The Netherlands – Thuja Capital’s Harrold van Barlingen was interviewed by C2W Magazine. Please find the article here.

Elbion AG acquires late-stage product candidate from DrugAbuse Sciences

Date: 19/01/2007

Leuven, Belgium – Elbion AG Acquires Late-Stage Product Candidate From DrugAbuse Sciences, Inc. For Treatment Of Alcohol Dependence

Elbion NV, a leading European drug discovery and development company, today announced it has acquired a number of product candidates from the French biotechnology company DrugAbuse Sciences. (more…)